Literature DB >> 7152156

Pediatric speech intelligibility test: performance-intensity characteristics.

S Jerger, J Jerger.   

Abstract

Performance-intensity (PI) functions for Pediatric Speech Intelligibility (PSI) test materials were obtained in 40 normal-hearing children between 3 and 6 yrs of age. PSI messages were monosyllabic words and sentences presented in quiet and in the presence of a competing speech message. The message-to-competition ratio was constant across intensity levels: +4 dB (words) and O dB (sentences). Maximum speech intelligibility scores were 100% correct in all children for all conditions. The steepness of the PSI-PI functions, defined by the intensity range yielding performance between 20 and 80%, ranged from 8 to 12 dB. Threshold levels (50% correct) ranged from 21 to 26 dB SPL. With one exception, chronological age did not significantly influence the steepness of PSI-PI functions. The exception was the increasing steepness with increasing age noted for sentences in competition. A significant chronological age developmental trend was noted for all speech threshold results.

Entities:  

Mesh:

Year:  1982        PMID: 7152156     DOI: 10.1097/00003446-198211000-00007

Source DB:  PubMed          Journal:  Ear Hear        ISSN: 0196-0202            Impact factor:   3.570


  3 in total

1.  A Longitudinal Study of Audiovisual Speech Perception by Children with Hearing Loss Who have Cochlear Implants.

Authors:  Tonya R Bergeson; David B Pisoni; Rebecca A O Davis
Journal:  Volta Rev       Date:  2003

2.  Measuring open-set, word recognition in school-aged children: Corpus of monosyllabic target words and speech maskers.

Authors:  Angela Yarnell Bonino; Ashley R Malley
Journal:  J Acoust Soc Am       Date:  2019-10       Impact factor: 1.840

3.  Developmental changes in word recognition threshold from two to five years of age in children with different middle ear status.

Authors:  Amanda J Hall; Kevin J Munro; Jon Heron
Journal:  Int J Audiol       Date:  2007-07       Impact factor: 2.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.